D-Finitive Cell Technologies expands global cell solutions’ 3D cell culture offerings

D-Finitive Cell Technologies (DCT) and Global Cell Solutions (GCS) announced a licensing agreement for the distribution of two new products, animal-origin-free cell culture and cryopreservation media for cell culture.

Global Cell Solutions, Inc., located in Charlottesville, Va., provides a unique approach to 3D cell culture which will enable the next generation of scientific breakthroughs in medicine, therapeutics, biotechnology and pharmaceuticals research. The company’s products and services, centered on its proprietary GEM™ substrate and BioLevitator™, are focused on delivering an innovative solution that provides life sciences with new cell culture tools and solutions leading to drug discovery and human therapies as well as predictive biomanufacturing processes. For more information, visit www.globalcellsolutions.com.

“We uniquely formulated 3D CyroShield AOF™ , a cryopreservation medium, to allow a number of cell lines to survive the freezing and recovery process while allowing cells to remain attached to Global Cell Solutions’ “GEM” substrate,” stated Donald P. DeLuca, Jr., President of D-Finitive. “In addition, 3D-Stem SFM™ is a powerful animal origin free medium to increase yield and quality of stem and other cells We look forward to working closely with GCS to introduce more specialty cell culture products.”

“We are pleased to be able to leverage D-Finitive’s expertise to not only expand our product portfolio, but also offer a more comprehensive 3D cell culture solution to our customers. The cooperation with Dr. Paul Price and his scientific team will surely continue to meet the increasing complexity and demands of cell-based research and therapeutics,” said Uday Gupta, Global Cell’s President and CEO.

D-Finitive Cell Technologies located in Charleston, S.C. specializes in providing hematopoietic and other stem cell products, including cell culture media, and innovative growth factor cocktails . DCT provides contract R&D and custom products to Industrial Partners and Distributors worldwide. Its team holds international acclaim in the cellular research arena with extensive competencies in growth formulations, bio-production, stem cell research and manufacturing. The staff is headed by Paul Price, Ph.D., who is the Chief Scientific Officer. Dr. Price is internationally recognized as a leader in serum-free and animal-origin-free cell culture media development. He is the creator of many products currently used in the field of cellular research, including both stem and differentiated cells, and has played a key role in the development of formulations for the growth of cells used in the vaccine and bio-production industries. For more information about D-Finitive Cell Technologies please visit its website at dcelltech.com.